Ireland
--:--IST
Recruiting Phase 1

A Study of LAD106 in Healthy Adult Participants

NCT07471932 · tracked via the Priya Life Science Netherlands tracker
Phase
Phase 1
Started
2026-02-17
Last updated
2026-05-15

Condition(s) studied

Healthy Volunteers

Investigational drug(s) / intervention(s)

LAD106Lebrikizumab →Placebo

LAD106: LAD106 will be administered.

Lebrikizumab: Lebrikizumab will be administered.

Placebo: Placebo matching LAD106 will be administered.

Study summary

The main aim of this study is to assess the safety, tolerability, pharmacokinetics (PK), immunogenicity and pharmacodynamics (PD) of single ascending doses of LAD106 (Part A) and multiple ascending doses of LAD106 (Part B) in human healthy participants.

Eligibility

Sex
ALL
Min age
18 Years
Max age
45 Years
Healthy volunteers
Accepted
Inclusion Criteria: 1. Signed informed consent and willing and able to comply with the study protocol. 2. Healthy men or women,18 to 45 years of age (inclusive) at screening. 3. Female participants agree to use effective contraception. 4. Male volunteers agree to use barrier protection when they engage in sexual relations with women of child-bearing potential (WOCBP) or lactating women. 5. Body mass index (BMI) between 18 and 32 kilograms per square meter (kg/m\^2), inclusive, and with a minimum bodyweight of 50 kg. 6. Has the ability to communicate well with the Investigator in Dutch language and willing to comply with the study restrictions. Exclusion Criteria: 1. Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the participant in the opinion of the investigator. 2. Clinically significant abnormalities, as judged by the Investigator, in laboratory test results. 3. Use of any medications (prescription or over-the-counter \[OTC\]), within 14 days prior to IMP dosing or less than 5 half-lives (whichever is longer). An exception is made for paracetamol (up to 4 g/day). 4. If a woman, pregnant, or breast-feeding, or planning to become pregnant during the study.

Primary outcome measure(s)

  • Part A (SAD): Number of Participants with Treatment-emergent Adverse Events (TEAEs) and Severity of TEAEs — From start of study drug up to follow-up (Day 81)
  • Part B (MAD): Number of Participants with TEAEs and Severity of TEAEs — From start of study drug up to follow-up (Day 104)

Trial sites (1)

FacilityCityRegionStatus
Centre for Human Drug Research (CHDR) Phase 1 Unit Leiden Netherlands Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07471932 on ClinicalTrials.gov ↗ ← All trials in the Netherlands